Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach

被引：13

作者：

Mony, Laetitia ^{[3
,4
]}

Triballeau, Nicolas ^{[1
,2
,3
]}

Paoletti, Pierre ^{[4
]}

Acher, Francine C. ^{[3
]}

Bertrand, Hugues-Olivier ^{[1
]}

机构：

[1] Parc Club Orsay Univ, Accelrys SARL, F-91898 Orsay, France

[2] Galapagos SASU, F-93230 Romainville, France

[3] Univ Paris 05, Chim & Biochim Pharmacol & Toxicol Lab, CNRS, UMR 8601, F-75006 Paris, France

[4] Ecole Normale Super, Inst Biol, CNRS, U1024,UMR 8197,INSERM, F-75005 Paris, France

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 18期

关键词：

Glutamate; NMDA; NR2B-selective antagonist; Pharmacophore; Virtual screening; D-ASPARTATE RECEPTOR; SUBTYPE-SELECTIVE INHIBITORS; AMINO-TERMINAL DOMAIN; BIOLOGICAL EVALUATION; BINDING DOMAIN; NR2B SUBUNIT; POTENT; IFENPRODIL; SERIES; MECHANISMS;

D O I：

10.1016/j.bmcl.2010.07.043

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report the identification of a novel NR2B-selective NMDAR antagonist with an original scaffold, LSP10-0500. This compound was identified by a virtual high-throughput screening approach on the basis of a quantitative pharmacophore model of NR2B-specific NMDAR antagonists. A SAR study around LSP10-0500 is also described. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：5552 / 5558

页数：7

共 39 条

[1]

[Anonymous], 2006, PHARMACOPHORES PHARM

[2] Oxamides as novel NR2B selective NMDA receptor antagonists [J].

Barta-Szalai, G ;

Borza, I ;

Bozó, É ;

Kiss, C ;

Agai, B ;

Proszenyák, A ;

Keserü, GM ;

Gere, A ;

Kolok, S ;

Galgóczy, K ;

Horváth, C ;

Farkas, S ;

Domány, G .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (15) :3953-3956

[3]

Bohm H.J., 2000, VIRTUAL SCREENING BI

[4] NR2B selective NMDA antagonists:: The evolution of the ifenprodil-type pharmaeophore [J].

Borza, Istvan ;

Domany, Gyorgy .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (07) :687-695

[5] (3R,4S)-3-[4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol:: A conformationally restricted analogue of the NR2B subtype-selective NMDA antagonist (1S,2S)-1-(4-hydroxyphenyl)-2(4-hydroxy-4-phenylpiperidino)-1-propanol [J].

Butler, TW ;

Blake, JF ;

Bordner, J ;

Butler, P ;

Chenard, BL ;

Collins, MA ;

DeCosta, D ;

Ducat, MJ ;

Eisenhard, ME ;

Menniti, FS ;

Pagnozzi, MJ ;

Sands, SB ;

Segelstein, BE ;

Volberg, W ;

White, WF ;

Zhao, DY .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (07) :1172-1184

[6] 4-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists [J].

Büttelmann, B ;

Alanine, A ;

Bourson, A ;

Gill, R ;

Heitz, MP ;

Mutel, V ;

Pinard, E ;

Trube, G ;

Wyler, R .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (10) :1759-1762

[7]

Coughenour LL, 1997, J PHARMACOL EXP THER, V280, P584

[8] NMDA receptor subunits: diversity, development and disease [J].

Cull-Candy, S ;

Brickley, S ;

Farrant, M .

CURRENT OPINION IN NEUROBIOLOGY, 2001, 11 (03) :327-335

[9]

Dingledine R, 1999, PHARMACOL REV, V51, P7

[10]

Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285

← 1 2 3 4 →